Tag Archives: Biosimilar

Mvasi by Amgen is the First FDA Approved Cancer Biosimilar

FDA Approves the First Cancer Biosimilar Mvasi by Amgen is Hitting the US Market   Yesterday the FDA announced that Amgens biosimilar to Avastin, known as Mvasi (bevacizumab-awwb) was approved for five different types of cancer: Non-squamous non-small cell lung cancer (NSCLC) – in combination with chemotherapy Metastatic colorectal cancer (mCRC) – in combination with chemotherapy Glioblastoma Metastatic renal […]